Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gentian Diagnostics ASA ( (DE:6FK) ) has issued an update.
Gentian Diagnostics ASA announced that INSR AS and Norda ASA have each acquired 614,251 shares in the company, representing about 3.98% of the total outstanding shares per entity. Together with other associated groups, they now hold approximately 22.2% of Gentian’s total shares, potentially influencing the company’s strategic direction despite no formal roles held by board member Fredrik Thoresen in the purchasing companies.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA operates in the diagnostics industry, focusing on developing and manufacturing innovative diagnostic tests. The company is known for its products that enhance laboratory efficiency and improve patient outcomes, serving a global market.
YTD Price Performance: 23.12%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: €65.18M
Find detailed analytics on 6FK stock on TipRanks’ Stock Analysis page.